Cancer Treatment-induced Oral Mucositis - Anticancer Research

259 Cerchietti LC, Navigante AH, Bonomi MR, Zaderajko MA,
Menendez PR, Pogany CE and Roth BM: Effect of topical
morphine for mucositis-associated pain following concomitant
chemoradiotherapy for head and neck carcinoma. Cancer
95(10): 2230-2236, 2002.
260 Cerchietti LC, Navigante AH, Korte MW, Cohen AM,
Quiroga PN, Villaamil EC, Bonomi MR and Roth BM:
Potential utility of the peripheral analgesic properties of
morphine in stomatitis-related pain: a pilot study. Pain 105(1-
2): 265-273, 2003.
261 Buntzel J, Kuttner K, Frohlich D and Glatzel M: Selective
cytoprotection with amifostine in concurrent radiochemotherapy
for head and neck cancer. Ann Oncol May 9(5): 505-509, 1998.
262 Vacha P, Fehlauer F, Mahlmann B, Marx M, Hinke A,
Sommer K, Richter E and Feyerabend T: Randomized phase
III trial of postoperative radiochemotherapy +/- amifostine in
head and neck cancer. Is there evidence for radioprotection?
Strahlenther Onkol 179(6): 385-389, 2003.
263 Vacha P, Marx M, Engel A, Richter E and Feyerabend T: Side
effects of postoperative radiochemotherapy with amifostine
versus radiochemotherapy alone in head and neck tumors.
Preliminary results of a prospective randomized trial.
Strahlenther Onkol 175 Suppl 4: 18-22, 1999.
264 Peters K, Mucke R, Hamann D, Ziegler PG and Fietkau R:
Supportive use of amifostine in patients with head and neck
turmors undergoing radio-chemotherapy. Is it possible to limit
the duration of the application of amifostine? Strahlenther
Onkol 175 Suppl 4: 23-26, 1999
265 Buentzel J, Micke O, Adamietz IA, Monnier A, Glatzel M and
de Vries A: Intravenous Amifostine during chemoradiotherapy
for head-and-neck cancer: a randomized placebo-controlled
phase III study. Int J Radiat Oncol Biol Phys 64(3): 684-691,
2006.
266 Suntharalingam M, Jaboin J, Taylor R, Wolf Jm, Banglore M,
Van Echo D and Ord R: The evaluation of amifostine for
mucosal protection in patients with advanced loco-regional
squamous cell carcinomas of the head and neck (SCCHN)
treated with concurrent weekly carboplatin, paclitaxel, and
daily radiotherapy(RT). Semin Oncol 31(6 Suppl 18): 2-7,
2004.
267 Adamietz IA, Rahn R, Bottcher HD, Schafer V, Reimer K and
Fleischer W: Prophylaxis with povidone-iodine against
induction of oral mucositis by radiochemotherapy. Support
Care Cancer 6(4): 373-377, 1998.
268 Naidu MU, Ramana GV, Ratnam SV, Sudhavani T, Naidu KJ,
Roy P, Suresh P, Rani PU and Mohan IK: A randomized
double-blind, parallel, placebo-controlled study to evaluate the
efficacy of MF5232 (Mucotrol), a concentrated oral gel wafer, in
the treatment of oral mucositis. Drugs R D 6(5): 291-298, 2005.
269 Lieschke GJ and Burgess AW: Granulocyte colony-stimulating
factor and granulocyte-macrophage colony-stimulating factor
(1). N Engl J Med 327(1): 28-35, 1992.
270 Bennett NT and Schultz GS: Growth factors and wound
healing: biochemical properties of growth factors and their
receptors. Am J Surg 165(6): 728-737, 1993.
271 Braunstein S, Kaplan G, Gottlieb AB, Schwartz M, Walsh G,
Abalos RM, Fajardo TT, Guido LS and Krueger JG: GM-CSF
activates regenerative epidermal growth and stimulates
keratinocyte proliferation in human skin in vivo. J Invest
Dermatol 103(4): 601-604, 1994.
1124
ANTICANCER RESEARCH 27: 1105-1126 (2007)
272 da Costa RM, Aniceto C, Jesus FM and Mendes M: Quick
healing of leg ulcers after molgramostim. Lancet 344(8920):
481-482, 1994.
273 Jyung RW, Wu L, Pierce GF and Mustoe TA: Granulocytemacrophage
colony-stimulating factor and granulocyte colonystimulating
factor: differential action on incisional wound
healing. Surgery 115(3): 325-334, 1994.
274 Masucci G: New clinical applications of granulocytemacrophage
colony-stimulating factor. Med Oncol Sep 13(3):
149-154, 1996.
275 Kaplan G, Walsh G, Guido LS, Meyn P, Burkhardt RA,
Abalos RM, Barker J, Frindt PA, Fajardo TT, Celona R et al:
Novel responses of human skin to intradermal recombinant
granulocyte/macrophage-colony-stimulating factor: Langerhans
cell recruitment, keratinocyte growth, and enhanced wound
healing. J Exp Med 175(6): 1717-1728, 1992.
276 Raderer M, Kornek G, Hejna M, Koperna K, Scheithauer W
and Base W: Topical granulocyte-macrophage colonystimulating
factor in patients with cancer and impaired wound
healing. J Natl Cancer Inst 89(3): 263, 1997.
277 Zaghloul MS, Dorie MJ and Kallman RF: Interleukin 1
increases thymidine labeling index of normal tissues of mice
but not the tumor. Int J Radiat Oncol Biol Phys 29(4): 805-
811, 1994.
278 Zaghloul MS, Dorie MJ and Kallman RF: Interleukin-1
modulatory effect on the action of chemotherapeutic drugs
and localized irradiation of the lip, duodenum, and tumor. Int
J Radiat Oncol Biol Phys 26(3): 417-425, 1993.
279 Dorr W, Spekl K and Farrell CL: The effect of keratinocyte
growth factor on healing of manifest radiation ulcers in mouse
tongue epithelium. Cell Prolif 35 Suppl 1: 86-92, 2002.
280 Farrell CL, Rex KL, Chen JN, Bready JV, DiPalma CR,
Kaufman SA, Rattan A, Scully S and Lacey DL: The effects of
keratinocyte growth factor in preclinical models of mucositis.
Cell Prolif 35 Suppl 1: 78-85, 2002.
281 Dorr W, Noack R, Spekl K and Farrell CL: Modification of
oral mucositis by keratinocyte growth factor: single radiation
exposure. Int J Radiat Biol 77(3): 341-347, 2001.
282 Potten CS, Booth D, Cragg NJ, Tudor GL, O'Shea JA, Booth
C, Meineke FA, Barthel D and Loeffler M: Cell kinetic studies
in the murine ventral tongue epithelium: mucositis induced by
radiation and its protection by pretreatment with keratinocyte
growth factor (KGF). Cell Prolif 35 Suppl 1: 32-47, 2002.
283 Dorr W, Spekl K and Farrell CL: Amelioration of acute oral
mucositis by keratinocyte growth factor: fractionated
irradiation. Int J Radiat Oncol Biol Phys 54(1): 245-251, 2002.
284 Dorr W, Bassler S, Reichel S and Spekl K: Reduction of
radiochemotherapy-induced early oral mucositis by
recombinant human keratinocyte growth factor (palifermin):
experimental study in mice. Int J Radiat Oncol Biol Phys
62(3): 881-887, 2005.
285 Sonis ST, Costa JW Jr, Evitts SM, Lindquist LE and Nicolson
M: Effect of epidermal growth factor on ulcerative mucositis
in hamsters that receive cancer chemotherapy. Oral Surg Oral
Med Oral Pathol 74(6): 749-755, 1992.
286 Dumbrigue HB, Sandow PL, Nguyen KH and Humphreys-
Beher MG: Salivary epidermal growth factor levels decrease in
patients receiving radiation therapy to the head and neck. Oral
Surg Oral Med Oral Pathol Oral Radiol Endod 89(6): 710-716,
2000.